Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 1125 N. Charles St, Baltimore, MD 21201.

Vtech Holdings ADR (VTKLY)

$5.64 0.01 (0.18%)

13:41 EDT VTKLY Stock Quote Delayed 30 Minutes

Volume:

Previous Close $5.65

Market Cap 1.42B

PE Ratio -

EPS -

Volume (Avg. Vol.) 4,068

Day's Range 5.44 - 5.65

52-Week Range 5.48 - 10.35

Dividend & Yield 0.70 (12.40%)

VTKLY Stock Predictions, Articles, and Vtech Holdings ADR News

From the Web

Homology Medicines (FIXX) Looks Good: Stock Adds 8% in Session

From Zacks Investment Research Jul 8, 2020

Homology Medicines (FIXX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Bullish Two Hundred Day Moving Average Cross - VYGR

From Market News Video Jun 10, 2020

In trading on Wednesday, shares of Voyager Therapeutics Inc (VYGR) crossed above their 200 day moving average of $13.18, changing hands as high as $13.43 per share. Voyager Therapeutics Inc shares are currently trading up about 2.8% on the day..

Is Voyager Therapeutics, Inc. (NASDAQ:VYGR) Expensive For A Reason? A Look At Its Intrinsic Value

From Simply Wall St Jun 10, 2020

In this article we are going to estimate the intrinsic value of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by taking the foreast future cash flows of the company and discounting them back<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vygr/voyager-therapeutics/news/is-voyager-therapeutics-inc-nasdaqvygr-expensive-for-a-reason-a-look-at-its-intrinsic-value/">Read More...</a></div>

Nomura Maintains Their Buy Rating on Voyager Therapeutics (VYGR)

From Analyst Ratings May 13, 2020

In a report issued on May 11, Christopher Marai from Nomura maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a price target of $16.00. The company’s shares closed last Wednesday at $11.37. According to TipRanks.com, Marai is a 4-star analyst with an average return of 3.8% and a 50.7% success rate.

Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering

From Barron's May 12, 2020

This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web.

Should You Buy Voyager Therapeutics (VYGR) Ahead of Earnings?

From Zacks Investment Research May 11, 2020

Voyager Therapeutics (VYGR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.